Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease

Update Il y a 4 ans
Reference: EUCTR2012-004180-43

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Primary objectives for rivaroxaban randomization: •To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke, or cardiovascular death in subjects with CAD or PAD •To determine whether rivaroxaban 5 mg bid compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction, stroke or cardiovascular death in subjects with CAD or PAD


Inclusion criteria

  • Prevention of major cardiovascular events in patients with coronary or peripheral artery disease